A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in In Med Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 56,666 shares of INM stock, worth $259,530. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,666
Previous 12,097 368.43%
Holding current value
$259,530
Previous $3,000 333.33%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.12 - $0.43 $5,348 - $19,164
44,569 Added 368.43%
56,666 $13,000
Q2 2024

Aug 14, 2024

SELL
$0.22 - $0.37 $138 - $232
-628 Reduced 4.94%
12,097 $3,000
Q1 2024

May 15, 2024

SELL
$0.32 - $0.44 $6,810 - $9,364
-21,284 Reduced 62.58%
12,725 $4,000
Q4 2023

Feb 14, 2024

BUY
$0.33 - $0.99 $11,222 - $33,668
34,009 New
34,009 $14,000

Others Institutions Holding INM

About InMed Pharmaceuticals Inc.


  • Ticker INM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 908,761
  • Market Cap $4.16M
  • Description
  • InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in precl...
More about INM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.